Method for carrying out non-isotopic immunoassays, labeled analytes and kits for use in such assays
Patent 4378428 Issued on March 29, 1983. Estimated Expiration Date: March 30, 2001. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.
435/7.23, Tumor cell or cancer cell435/188, Stablizing an enzyme by forming a mixture, an adduct or a composition, or formation of an adduct or enzyme conjugate435/7.4, To identify an enzyme or isoenzyme435/7.7, Assay in which a label present is an apoenzyme, prosthetic group, or enzyme cofactor435/7.8, Involving nonmembrane bound receptor binding or protein binding other than antigen-antibody binding435/7.93, Competitive assay435/810, PACKAGED DEVICE OR KIT435/967, STANDARDS, CONTROLS, MATERIALS (E.G., VALIDATION STUDIES, BUFFER SYSTEMS, ETC.)435/968, HIGH ENERGY SUBSTRATES (E.G., FLUORESCENT, CHEMILUMINESCENT, RADIOACTIVE, ETC.)435/971, CAPTURE OF COMPLEX AFTER ANTIGEN-ANTIBODY REACTION435/975, KIT436/500, THYROID HORMONE TESTS (E.G., T3, T4, TBG, TSH, ETC.)436/518, INVOLVING AN INSOLUBLE CARRIER FOR IMMOBILIZING IMMUNOCHEMICALS436/528, Carrier is organic436/532, Antigen or antibody attached to a carrier via bridging agent436/536, INVOLVING IMMUNE COMPLEX FORMED IN LIQUID PHASE436/544, Producing labeled antigens530/345, Chemical aftertreatment, e.g., acylation, methylation, etc.530/389.2, Binds hormone, lymphokine, cytokine, or other secreted growth regulatory factor, differentiation factor, intercellular mediator, or neurotransmitter (e.g., insulin, human chorionic gonadotropin, glucagon, cardiodilatin, interleukin, interferon, norepinephrine, epinephrine, acetylcholine, etc.)530/389.3, Binds plasma protein, serum protein, or fibrin (e.g., clotting factor, fibrinolytic factor, complement factor, immunoglobulin, apolipoprotein, etc.)530/389.7, Binds cancer cell or component or product thereof (e.g., cell-surface antigen, etc.)530/389.8, Binds drug, hapten, hapten-carrier complex, or specifically-identified chemical structure (e.g., theophylline, digoxin, etc.)530/404, Sulfur containing reactant530/408, Sulfur containing reactant930/10, PEPTIDE OR PROTEIN SEQUENCE930/240Enzyme or isoenzyme
A highly sensitive, immunoassay method for determining the amount of an analyte in a sample containing a known analyte in an unknown concentration is provided. Sample; a polypeptide-labeled analog of the analyte, an antibody specific for said analyte, a polypeptide partner capable of non-covalently binding with the polypeptide-labeled analyte to form a complex having catalytic activity, and a substrate capable of being converted to a reporter molecule by the catalytic activity of said complex are brought together in a medium. The polypeptide-labeled analyte analog is capable of competitively binding to the antibody and the polypeptide partner, the antibody inhibiting the formation of a catalytically active complex in the absence of analyte, and the concentrations of the antibody, polypeptide partner and polypeptide-labeled analyte are such as to cause varying amounts of analyte to be directly related to the conversion of the substrate to the reporter molecule. Conversion of the substrate to the reporter molecule is then determined, and compared to conversions of substrate to reporter molecule obtained with known concentrations of the analyte.
Other References
Gonnelli et al., "Interaction of S-Protein with S-Peptides-Tyroxine Conjucate", Italian Journal Biochemistry, vol. 29 (1980), pp. 234-235
J. F. Burd, R. C. Wong, J. E. Feeney, R. J. Carrico and R. C. Boguslaski, Clin. Chem., 23, (1977), 1402
F. Kohen, Z. Hollander and R. C. Boguslaski, Jour. of Steroid Biochem., 11, (1979), 161
F. Kohen, Z. Hollander, F. Yeager, R. J. Carrico and R. C. Boguslaski, Enzyme-Labeled Immunoassay of Hormones and Drugs, edit. by S. B. Pal, W. deGruiter, Berlin & NY, (1978), 67-79
R. J. Carrico, J. E. Christner, R. C. Boguslaski and K. K. Young, Anal. Biochem., 72, (1976), 271
M. J. O'Sullivan, J. W. Bridges and V. Mark, Annals of Clinical Biochemistry, 19, (1977), 221
Chemical Rubber Company Enzyme Immunoassay, edited by Edward T. Maggio, (1980), 105-134
H. Rubsamen, R. Khandler and H. Witzel, Hoppe-Seyler's Z. Physiol Chem., 355, (1974), 687
F. M. Richards, Proc. Nat'l. Acad. Sci. U.S., 44, (1958), 162
F. M. Richards and P. J. Vithayahil, J. Biol Chem., 234, (1959), 1459
F. M. Richards and H. W. Wyckoff, The Enzymes, (P. D. Boyer, Ed.), Academic Press, 3d Ed., vol. 4, (1978), 647-806, London and New York
G. W. Welling, J. A. Lenstra, J. J. Beintema, FEBS Letters, 63, (1979), 89
M. C. Lin, J. Biol. Chem., 245, (1970), 6726
M. C. Lin, B. Gutte, S. Moore and R. B. Merrifield, J. Biol. Chem., 245, (1970), 5169
M. C. Lin, B. Guth, D. G. Caldi, S. Moore and R. B. Merrifield, J. Biol. Chem., 247, (1972), 4768
S. Lin, M. Villarego and I. Zabin, Biochem. Biophys. Research Commun., 40, (1970), 249
D. V. Marinkovic and J. N. Marinkovic, Biochem, J., 155, (1976), 209
S. L. Morrison and D. Zipser, J. Mol. Biol., 50, (1970), 359
J. V. Welply, W. Mandecki, A. V. Fowler and I. Zabin, Biochem. Biophys. Res. Commun., 93, (1980), 223
F. Celada and I. Zabin, Biochem., 18, (1979), 404
F. M. Finn and K. Hofmann, Accounts of Chem. Research, 6, (1973), 170
A. Rochi, F. Marchiori, L. Maroder, A. Fontana and E. Scoffone, Gazz. Chim. Ital., 96, (1966), 1537
L. Maroder, A. Rochi, F. Marchiori, A. Fontana and E. Scoffone, J. Amer. Chem. Soc., 91, (1961), 3921
R. Rochi, L. Maroder, F. Marchiori, E. Ferrarese and E. Scoffone, J. Amer. Chem. Soc., 90, (1968), 5885
F. Marchiori, R. Rochi, L. Maroder and E. Scoffone, Gazz. Chim. Ital., 96, (1966), 1549
H. K. Kricheldorf, Angew. Chem., 87, (1975), 517
P. Cuatrecases, M. Wilchek and C. B. Anfinsen, "The Action of Staphyloccal Nuclease and Synthetic Substrates," Synthetic Substrates of Staphyloccas Nuclease, vol. 8, No. 6, Jun. 1969, pp. 2277-2283
C. Cook, J. A. Kepler, H. Dix Christiansen, Res. Comm. Chem. Path. Pharma., 5, (1973), 767
March 30, 2001. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.
